Summary of LUME-Lung 1 Results
LUME-Lung 1 met its primary endpoint
and demonstrated:
•
Significant prolongation of
PFS regardless of histology
•
Median PFS 3.4 vs 2.7, HR=0.79 (95% CI: 0.68–0.92), p=0.0019
•
Significant improvement in
OS in patients with adenocarcinoma
•
Median OS 12.6 vs 10.3 months, HR=0.83 (95% CI: 0.70–0.99),
p=0.0359
•
Time since start of 1
st
line therapy
<9 months
(HR 0.75, p=0.0073,
median OS 7.9 to 10.9 mo)
•
Manageable safety profile
•
Commonly reported AEs included gastrointestinal events and
reversible liver enzyme elevations
•
No compromise to patients’ self-reported QoL
